Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dotinurad hepatic effects in gout with MASLD
ChiCTR2600133375Phase 4Not yet recruiting
- Sponsor
- Zhejiang Hospital
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dotinurad in gout and metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Zhejiang Hospital. Primary endpoint: Change in serum gamma-glutamyl transferase. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
dotinurad
03
Conditions
goutmetabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on ChiCTR2600133375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133375.